Background {#Sec1}
==========

Elevated blood pressure (BP) is a leading preventable cause of cardiovascular disease (CVD) and premature death and disability globally \[[@CR1], [@CR2]\]. Hypertension treatment and control rates are low worldwide, but worst in low- and middle-income countries (LMICs), where less than 37% of patients are on treatment and 13% have adequately controlled BP \[[@CR3]\]. Interventions to strengthen LMIC health systems to control hypertension are urgently needed \[[@CR4]\].

Most LMICs utilize a tiered health care system, spanning a primary, secondary, and tertiary care continuum, with the goal of broadening access to basic health services through decentralizing, and decongesting higher-level facilities \[[@CR5], [@CR6]\]. The tiers are connected by referral networks which enable triaged access to different levels of care depending on patients' needs. The effectiveness of these networks, however, is often inadequate, characterized by suboptimal rates of referral completion \[[@CR7]--[@CR10]\]. Key barriers to successful referral completion include logistical issues, cost, knowledge gaps among providers, lack of communication across levels of care, and inability to track referred patients \[[@CR8], [@CR11]--[@CR15]\]. Successful referral completion has been shown to improve CVD care in high-income countries \[[@CR16], [@CR17]\] as well as HIV care in LMICs \[[@CR18], [@CR19]\]. However, studies evaluating interventions to improve referral networks for hypertension in LMICs are lacking.

Health information technology (HIT) and peer support target many of the barriers to successful referral completion. HIT interventions, such as electronic medical records and mobile technology in health tools (mHealth), are a key strategy in improving patient encounter documentation, data capture, inter-provider communication, and follow-up for non-communicable disease management in LMICs \[[@CR20]--[@CR23]\]. Peer support approaches leverage the unique patient--patient interactions built on shared disease experiences to influence behavior change \[[@CR24]\]. Peer navigators have been used to improve linkage and retention in care for patients with HIV, mental health, and cancer \[[@CR25]--[@CR31]\], and even facilitate referral completion for cancer care \[[@CR32]\].

The *St*rengthening *Re*ferral *N*etworks for Mana*g*ement of Hyper*t*ension across the *H*ealth *S*ystem (STRENGTHS) study is a cluster randomized control trial that will evaluate the effectiveness and cost-effectiveness of a combined HIT and peer support intervention on referral completion, BP improvement, and CVD risk reduction in Kenya. The STRENGTHS study uses a transdisciplinary implementation research approach and is the first study to rigorously evaluate such an intervention to strengthen referral networks in LMICs.

Methods/design {#Sec2}
==============

Setting {#Sec3}
-------

The Academic Model Providing Access to Healthcare (AMPATH) program is an academic global health partnership between Moi Teaching and Referral Hospital (MTRH), Moi University College of Health Sciences, and a consortium of North American universities led by Indiana University \[[@CR33]--[@CR35]\]. In recognition of the growing non-communicable disease (NCD) burden in LMICs \[[@CR36]\], AMPATH has established a Chronic Disease Management (CDM) Program in collaboration with the Ministry of Health (MOH). The CDM Program has enrolled over 15,000 patients with hypertension at 69 facilities spanning all levels of the health system, alongside system-wide approaches to task redistribution, use of mHealth and electronic decision support, and ensuring a reliable supply of medicines for hypertension and other NCDs \[[@CR37]--[@CR39]\]. At MTRH, there is an inpatient cardiac critical care unit, a specialist outpatient cardiology clinic, and advanced cardiac diagnostic services \[[@CR40]\]. It is within this clinical infrastructure that we plan to develop and test our intervention.

We will conduct this study within the AMPATH CDM program's catchment area across eight geographically separate referral networks (Fig. [1](#Fig1){ref-type="fig"}). The Kenyan public-sector health system functionally coalesces into the three traditional health system levels---primary, secondary, and tertiary---and each referral network in our catchment area is centered around a secondary-level health facility: Kitale, Webuye, Kocholya, Turbo, Mosoriot, Burnt Forest, Bunyala, and Butula (Fig. [1](#Fig1){ref-type="fig"}). Each of these serves as the link between the common tertiary-level center, MTRH, staffed by specialists and sub-specialists, and several primary-level health facilities that feed into it, staffed by clinical officers (mid-level providers) and nurses (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1AMPATH clinic sites and referral network clusters; Health system levels

Aims {#Sec4}
----

The purpose of this study is to use a transdisciplinary, implementation science research approach to strengthen referral networks to improve hypertension control and reduce CVD risk. Our central hypothesis is that HIT integrated with peer support will be effective and cost-effective in strengthening referral networks, improving BP control, and reducing CVD risk among patients with hypertension in western Kenya.

The aims of the STRENGTHS study (Fig. [2](#Fig2){ref-type="fig"}) are to: Conduct a baseline needs and contextual assessment, using a mixed-methods approach, for implementing and integrating HIT and peer support to strengthen referral networks for hypertension control. We will use these data to develop a contextually and culturally appropriate intervention using a participatory, iterative design process.Evaluate the effectiveness of HIT and peer support for hypertension control by conducting a two-arm cluster randomized trial comparing: 1) usual care for referrals vs 2) referral networks strengthened with an integrated HIT and peer support intervention. The primary outcome will be one-year change in systolic blood pressure (SBP). The key secondary clinical outcome will be CVD risk reduction, and the key secondary implementation outcomes will include referral process metrics such as referral appropriateness and completion rates. We will conduct mediation and moderation analyses to evaluate the interaction between referral network characteristics and intervention outcomes. We will also conduct a process evaluation \[[@CR41]\].Evaluate the incremental cost-effectiveness of HIT and peer support, in terms of costs per unit decrease in SBP, per percentage change in CVD risk score, and per disability-adjusted life year (DALY) saved. Fig. 2STRENGTHS study aims

Implementation framework {#Sec5}
------------------------

We are using the PRECEDE-PROCEED implementation science conceptual framework to help guide our study (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR42], [@CR43]\]. We chose the PRECEDE-PROCEED framework because of its participatory nature, multi-pronged evaluation approach, and explicit assessment of the multi-level factors that may affect the uptake and success of our intervention. PRECEDE-PROCEED has also been successful in developing interventions to promote cardiovascular health in low-income populations \[[@CR44]\]. Fig. 3PRECEDE-PROCEED implementation framework and conceptual model of change

Conceptual model {#Sec6}
----------------

Both HIT and peer support may strengthen referral networks, improve BP control, and reduce CVD risk through multiple mechanisms. HIT may address barriers to hypertension control at the provider and health system levels, by improving data quality, integrating and coordinating care across levels of the health system \[[@CR45]\], and improving communication between providers \[[@CR11]\]. The clinical decision support programmed into the HIT platform may also directly lead to improvements in referral appropriateness. Peer navigators may address barriers at the patient and health system levels, by helping patients navigate health system complexity and overcome barriers to health seeking behavior \[[@CR46]\]. By addressing these multi-level factors, we hypothesize that our intervention will change both the clinical environment as well as patient and provider behaviors, which, in turn, will lead to improvements in referral network characteristics and referral process metrics. This has the potential to improve the coordination of care for patients with hypertension across the health system, ultimately reducing BP and CVD risk.

Baseline needs and contextual assessment and participatory design process {#Sec7}
-------------------------------------------------------------------------

We will use a mixed-methods approach to conduct a baseline needs and contextual assessment for implementing an integrated HIT and peer support intervention for strengthening referral networks for hypertension control. This will include: 1) observational process mapping and gap assessment; 2) baseline referral network analysis; and 3) a combination of qualitative research methods to identify facilitators, barriers, contextual factors, and readiness for change that may impact implementation of the integrated STRENGTHS intervention.

Observational process mapping, a technique adapted from Lean Six Sigma, will be conducted in order to determine patient and data flow throughout the referral network at each level of the health system \[[@CR47], [@CR48]\]. We will use a standardized checklist, adapted from the Kenya Health Sector Referral Strategy \[[@CR49]\], to observe patient and data movement throughout the system, as well as detail the personnel, supplies, equipment, and logistics necessary for the referral network to be functional. To augment this, clinical staff and patients will be recruited by purposive and snowball sampling for semi-structured interviews in order to describe all the steps in the referral process, understand associated costs and how this affects referrals, clarify staff roles and responsibilities, delineate data sources and mechanisms for communication, and elicit perspectives on challenges and opportunities for improving referral networks \[[@CR47], [@CR48]\].

A baseline referral network analysis will be conducted by recruiting all AMPATH clinicians at every facility participating in the trial to complete a baseline survey of referral preferences and patterns. We will ask clinicians to indicate other clinicians who they go to for advice, who they discuss clinical issues with, and who they refer patients to for hypertension care. We will also analyze actual clinician-to-clinician referral patterns measured from the medical record. This will form the basis of the mediation and moderation analysis we will conduct once the trial is completed.

Qualitative methods will involve a combination of focus group discussions (FGDs), key informant interviews, and community *mabaraza*, conducted at each level of the health system within each of the six referral network clusters. *Mabaraza* are traditional community assemblies in East African culture and have been used as a novel methodology in community-based participatory research \[[@CR50], [@CR51]\]. We will use purposive sampling to recruit patients and clinical staff for the FGDs, and clinic leaders and health system administrators for the key informant interviews. For the mabaraza and FGDs, discussions will be allowed to deviate from the initial guiding discussion topics if additional relevant issues emerge, and participatory techniques will be used to elicit emotional elements and encourage group interaction. Thematic content analysis will be performed, using both deductive (a priori) and inductive (emerging) codes. We will also assess inter-coder reliability, and a kappa-statistic will be calculated.

After the baseline needs and contextual assessment is complete, we will use these data to inform a participatory, iterative design process to fully develop the integrated HIT and peer support STRENGTHS intervention \[[@CR52]--[@CR54]\] A "design team" including a facilitator, research staff, clinical staff, informatics staff, peer navigators, and patients will be formed. The design process will involve three phases: brainstorming, conceptualization, and creation. This design process will use the findings from the baseline needs and contextual assessment alongside input from this diverse group of stakeholders to inform the detailed development of the integrated HIT and peer support intervention protocol. Once the intervention model is developed, we will conduct additional FGDs to assess acceptability \[[@CR55]\], as well as a 3-month pilot of the intervention to evaluate feasibility \[[@CR56]\].

Cluster randomized trial {#Sec8}
------------------------

We will conduct a two-arm cluster randomized trial comparing usual care and referral networks strengthened with an integrated HIT and peer support intervention. The primary outcome measure will be one-year change in SBP and a key secondary outcome will be change in CVD risk score. There will be a total of eight clusters in the trial, four in each arm, with each cluster in a geographically distinct referral network within the overall AMPATH CDM program. First, each referral network cluster will be stratified by size of the health facility at the secondary level. Then cluster randomization will be done within each strata. Cluster randomization will be done using a computerized random number generator in a 1:1 allocation sequence between intervention and control groups. One of the investigators, separate from other research or clinical staff, will generate the allocation sequence and complete randomization. Study staff will then enroll participants in the trial. The trial flow chart is shown in Fig. [4](#Fig4){ref-type="fig"} and the SPIRIT figure is shown in Fig. [5](#Fig5){ref-type="fig"}. The SPIRIT checklist is provided in Additional file [1](#MOESM1){ref-type="media"}. Fig. 4Flow of cluster randomized trial Fig. 5STRENGTHS SPIRIT figure

Study participants {#Sec9}
------------------

Adult patients ≥ 18 years who are enrolled in AMPATH's CDM program with hypertension at any level of care, and who meet criteria for referral up or down the referral network, will be eligible for inclusion in the trial. Individual informed consent will be obtained by study staff. Criteria for "referral up" the network is defined as patients with hypertension who remain uncontrolled (SBP ≥ 140 or diastolic blood pressure (DBP) ≥ 90) on three or more anti-hypertensive medications, who have signs or symptoms of end-organ damage, or who have suspected secondary causes of hypertension. Criteria for "referral down" the network is defined as controlled BP (SBP \< 140 and DBP \< 90) for three or more consecutive visits and no evidence of new end-organ damage. Exclusion criteria include acute illness requiring immediate medical attention, terminal illness, and inability to provide informed consent.

Integrated HIT and peer support intervention {#Sec10}
--------------------------------------------

### Usual care {#Sec11}

For patients requiring referral up the network, the referring clinician writes a referral letter on a blank referral form. This referral letter is then given to the patient, who is responsible for presenting it to the receiving facility and arranging the referral visit. For patients requiring referral down the network, a counter-referral letter, and/or copies of clinical records, are given to the patient to take back to their primary facility, although in reality this is inconsistent.

### HIT plus peer support referral intervention {#Sec12}

Those randomized to the intervention group will receive clinical care for hypertension in the same manner as those randomized to the usual care group. Furthermore, refusal to participate in the trial or withdrawal from the trial will not affect clinical care provided. Reasons for referral will also be the same in the two groups. The change in referral process is the intervention (Fig. [6](#Fig6){ref-type="fig"}). Fig. 6STRENGTHS intervention

### Health information technology {#Sec13}

AMPATH uses the AMPATH Medical Record System (AMRS), a customized version of OpenMRS \[[@CR22]\] that is centrally hosted and accessed by tablet via the Internet. Our HIT intervention will augment AMRS to support a referral system in four ways: 1) communication---facilitate data sharing by all providers and peer navigators across all levels of the health system; 2) decision support---provide clinical decision support to facilitate appropriate patient referrals; 3) tracking---generation and sharing of real-time patient referral lists; and 4) dashboards---create a platform for monitoring key referral process metrics. The system will prompt for referral based on clinical algorithms built into the clinical decision support, but also will allow the provider to initiate a referral based on his/her clinical judgment. Providers and peer-navigators will access the referral dashboard for a clinic to review patient referrals and track the status of referred patients. Key referral process metrics, such as referral wait times and completion rates, will be available in real-time for providers and peer navigators to monitor and act upon. Additional functionality of the HIT platform will be developed from the participatory design process described above.

### Peer support {#Sec14}

The peer support component of the intervention will involve peer navigators at each level of the referral network---primary, secondary, and tertiary. Peer navigators are patients within the AMPATH CDM program who have well-controlled hypertension; they have the shared experience of living with hypertension and navigating the same health system as the patients enrolled in the trial. The peer support intervention has three main functions: 1) referral adherence---enhance communication between clinicians and patients to improve referral adherence; 2) navigation---help patients navigate the complex health system \[[@CR30]\]; and 3) psychosocial support---help patients overcome barriers to health seeking behavior. Referral adherence support will help enhance communication about the referral between the provider and patient by having a peer navigator meet with patients to review referral rationale and logistics. The second major role of the peer navigator is health system navigation, especially at the tertiary level. Here, the peer navigator can personally receive a referred patient and walk them through registration, scheduling, triage, and diagnostic work-up in order to streamline the referral process and ensure patients are not lost in the complexity of the system \[[@CR57]\]. Furthermore, peer navigators will meet with patients after the clinic visit to provide any follow-up navigation between the pharmacy, laboratory, or imaging. The third major role of the peer navigator is to provide psychosocial support, helping patients overcome individual-level barriers to health-seeking behaviors, drawing from the innate trust inherent in their shared disease experience \[[@CR24]\].

### Integrated HIT plus peer support {#Sec15}

The peer navigators will be equipped with a HIT tool, as described above, so they can see the same data as the clinicians in order to track and follow referred patients appropriately. When a clinician at the primary level refers a patient to a higher level of care, the peer navigator covering that patient's community catchment area will automatically be alerted via the HIT tool so they can contact and meet the patient and review referral logistics. The peer navigator will then complete a referral navigation form on the HIT tool, which will automatically trigger a notification to the clinician and peer navigator at the receiving facility. Communication between the peer navigators at each level of the health system will be automated via the HIT tool to ensure seamless communication and data-sharing. Peer navigators at all levels will be trained to use the HIT tools, understand the basics of clinical referral algorithms and processes, navigate the health system, and provide education, counseling, motivational interviewing, and psychosocial support. Prior to trial enrollment, all clinicians will be sensitized about the STRENGTHS trial and educated on the STRENGTHS intervention. This will be done to help standardize the intervention delivery across clusters as well as to improve adherence and fidelity to the intervention model.

Outcomes {#Sec16}
--------

The primary outcome is one-year absolute mean change in SBP. The BP measurement for inclusion in the trial, and used in the primary outcome analysis, will be standardized and conducted by trained study staff. The key secondary clinical outcome is one-year change in overall CVD risk as measured by the QRISK2 score, which has been validated for calculating 10-year CVD event risk for Black Africans \[[@CR58]--[@CR66]\]. Treatment effect will be average change in SBP and QRISK2 score from baseline to month 12 and will be estimated using an intention-to-treat approach with appropriately specified regression models. Other clinical secondary outcomes will include mortality, hospital admissions, CVD complications, change in CVD risk factors and behaviors, and medication adherence \[[@CR67]\]. The primary outcome and clinical secondary outcomes pertain to the individual participant level. We will also measure referral process metrics as key secondary implementation outcomes, including referral completion rates, median referral completion time, referral eligibility, referral indication, and referral appropriateness. Data will be collected on covariates we hypothesize may be related to our outcomes. These include patient demographics, socioeconomic and education status, clinical comorbidities, CVD risk factors, health behaviors, medication adherence, geographic location, referral level, provider level of training, and peer navigator and provider characteristics.

Statistical power {#Sec17}
-----------------

We expect that each of the six referral networks will enroll at least 200 participants. Given the longstanding history of the AMPATH CDM program and robust clinical infrastructure in our catchment area, as well as previous success in recruiting participants for community- and clinical-based research related to hypertension and other chronic diseases, we anticipate being able to successfully enroll our needed number of participants. To augment this, we have sensitized all participating AMPATH CDM staff on the STRENGTHS trial, and conducted training of clinicians on the AMPATH CDM hypertension treatment and referral guidelines. Through our baseline needs and contextual assessment (Aim 1), clinic staff have become well versed on the eligibility criteria and enrollment procedures, which will also help with recruitment for the trial. During our pilot testing, if we encounter difficulty with recruitment or enrollment, then we will put additional strategies in place to overcome this. We estimate a 10-mmHg reduction in SBP in the intervention arm compared to the usual care arm \[[@CR68]\]. For our power calculation, we set the type I and type II error rates at 5% and 20%, respectively. We account for within-cluster correlation using intra-class correlation (ICC) values ranging from 0.02 to 0.06 consistent with prior studies using SBP as the outcome \[[@CR69]\]. We analyze scenarios over a range of minimum detectable differences (MDD) assuming a standard deviation (SD) for change in SBP of 15 from the literature, with SD ranges from 10 to 20 \[[@CR69], [@CR70]\]. Finally, we assume that up to 15% of enrolled participants will be lost to follow-up. Table [1](#Tab1){ref-type="table"} presents expected power assuming a standard deviation of 15 for the comparison across different combinations of ICC and minimum detectable differences (MDD). Over a wide range of plausible ICC, with standard deviation fixed at 15, we will be able to detect a mean difference in change in SBP consistent with the published literature \[[@CR69], [@CR70]\] and our preliminary data \[[@CR71], [@CR72]\] with power greater than 80%. Table 1Estimated power over a range of ICC and MDD valuesMDDICC0.020.030.040.050.06436272219176655142363288774645650109689827467129997928782149999989591

Analytical approach {#Sec18}
-------------------

We will use an analysis of covariance model with cluster effects to estimate and draw inference about treatment effects for both primary and key secondary outcomes. The model specification is: $$\documentclass[12pt]{minimal}
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where y~ij~ is SBP at the end of follow-up for the ith individual in the jth cluster, b~ij~ is baseline SBP, and the indicators x~ij~ represent intervention group membership, with usual care as the reference. Hence, β coefficient represents the difference in mean change in SBP between usual care and the intervention. The intercept is α and γ~j~ is the effect of the jth cluster. Cluster effects γ~j~ will initially be modeled as fixed effects, but we will use a mixed model structure and assign a normal distribution if the data support this assumption. We will compare key independent variables across the trial arms to ensure balance of the randomization process and adjust the model to estimate treatment effects as needed. For modeling QRISK2, we will use the transformation log(−log (QRISK2)) because the risk score ranges from 0% to 100% \[[@CR73]\]. We will test the further hypotheses that changes in referral network characteristics and referral process metrics can mediate the effect of the intervention on CVD outcomes, and that baseline referral network characteristics can moderate the effect of the intervention on outcomes, by conducting a mediation and moderation analysis, respectively \[[@CR74], [@CR75]\]. Further details of the data management procedures and statistical methods, including approach to missing data, mediation and moderation analysis, and secondary outcomes, are available upon request from the authors.

Process evaluation {#Sec19}
------------------

We will use the Saunders Framework \[[@CR41]\] to conduct a process evaluation of the integrated HIT and peer support intervention. This process evaluation will be undertaken in order to monitor program implementation and better understand the relationship between intervention components and health outcomes. The Saunders Framework provides a systematic approach for guiding the evaluation of key implementation process measures across the following domains: fidelity (quality), dose delivered (completeness), dose received (exposure and satisfaction), recruitment, reach (participation rate), and context. Mixed quantitative and qualitative methods will be used to collect data from study participants and clinical staff, as well as from study and clinical encounter forms. This process evaluation will generate both formative and summative data \[[@CR76], [@CR77]\].

A combination of quantitative and qualitative approaches will be taken, including observation forms, checklists, surveys, record review, focus group discussions, and semi-structured interviews. Study participants, clinical staff, and study and clinical encounter forms will be the sources of data. Descriptive statistics will be generated for quantitative data, and thematic content analysis will be performed for qualitative data. Formative data will be reported iteratively to the study team and staff throughout the trial, while summative data will be reported at the end of the trial.

Cost-effectiveness analysis {#Sec20}
---------------------------

We will evaluate the incremental cost-effectiveness of HIT and peer support in terms of costs per unit change in SBP, per percentage change in CVD risk score, and per DALY saved. For each intervention arm, costs and potential cost offsets from the societal and payer perspectives will be captured using previously validated cost questionnaires used in Kenya for hypertension trials \[[@CR78]--[@CR80]\]. Study participants will complete one costing instrument, capturing healthcare utilization and expenditures, work loss, and transportation costs. All measures of burden will be monetized and, if there are differences across arms, used to quantify cost offsets from intervention delivery. Research staff will complete an additional costing instrument in order to capture all relevant labor, materials, supplies, and contracted services costs for all intervention activities. Only net incremental costs, after removing sunk costs and after factoring in cost offsets, will be included as the numerator in the cost-effectiveness analysis as these are the relevant costs for decision makers. We will also identify which activities drive the overall costs, and how costs would change if specific activities are added or eliminated. Effectiveness in terms of SBP and CVD risk score will be defined as above. DALY improvements will be estimated using well-defined relationships between blood pressure reductions and CVD DALYs averted \[[@CR81]\]. We will also conduct sensitivity analyses to gauge the influence of key assumptions on the resulting incremental cost-effectiveness ratio.

Discussion {#Sec21}
==========

The burden of hypertension and CVD in LMICs is immense, requiring a coordinated health system response. Ineffective referral networks in LMICs contribute substantially to CVD-related morbidity and mortality. The STRENGTHS study has been designed to strengthen referral networks in order to improve BP control and reduce CVD risk. The STRENGTHS study offers several innovative elements with some key advantages. First, while HIT and peer support are proven interventions to improve coordination of care and health outcomes, their application in an integrated fashion to address multi-level factors in order to improve referral networks for BP control and CVD risk reduction in LMICs is novel. Second, we are using a participatory design process to ensure our intervention model is culturally appropriate, context-specific, and responsive to community needs and local health system realities. Third, we use PRECEDE-PROCEED, applying an implementation science theoretical framework to guide our study. Fourth, we are evaluating for the possible mediating and moderating influence of referral network characteristics on intervention outcomes, as well as including a rigorous cost effectiveness analysis. Fifth, we are a team of transdisciplinary investigators with expertise in cardiology, internal medicine, pharmaceutical care, health systems, economics, informatics, social network analysis, qualitative methods, biostatistics, and implementation science. Finally, we are layering this implementation research approach onto the existing clinical care system, maximizing the likelihood, if successful, for continued adoption and sustainability. While this research is situated within a particular health system in a single country focused on a single disease outcome, we anticipate that both the methodology and results can be applied to other settings.

Our study has some limitations and challenges. First, our baseline needs and contextual assessment is critical to designing our intervention model and implementing our trial, and there may be resistance by the community to participation. To mitigate this, we will hold sensitization sessions among clinic staff and patients before initiation, and we have been successful with this approach in previous studies in this setting \[[@CR50], [@CR51], [@CR82]\]. Second, we are conducting a two-arm trial with a combined (HIT plus peer support) intervention group, rather than a four-arm trial studying each individual intervention component, plus a separate combined group. We will therefore not be able to determine which component of the intervention was responsible for the observed effects on the primary and secondary outcomes. We chose this approach because a four-arm trial, randomized at the level of the referral network cluster, would be difficult to power and logistically complex to implement in the context of the existing care program. Our process evaluation will help to elucidate which components of the intervention worked, and how they performed on key implementation measures. A third limitation is that blinding of the study participants and research staff is not possible due to the design of the intervention. This may lead to bias, although we do not anticipate this to be a major issue given integration into the existing care system and the geographically distinct clusters. Despite these limitations, we anticipate that the STRENGTHS study will generate important results and provide a scalable health systems intervention for chronic diseases globally.

Trial status {#Sec22}
============

The study-specific manual of operations and policies have been developed, and training of research and clinical care staff is being completed. The Data Safety and Monitoring Board has been formed. The baseline needs and contextual assessment of Aim 1 has been completed and data analysis is underway. Enrollment into the trial is planned to start in August 2019 and be completed by July 2010. This is study protocol version 6.0 and the version date is May 6, 2019.

Additional file
===============

 {#Sec23}

Additional file 1:SPIRIT 2013 Checklist: Strengthening Referral Networks for Management of Hypertension Across the Health System (STRENGTHS) in western Kenya: a study protocol of a cluster randomized trial. (DOCX 54 kb)

AMPATH

:   Academic Model Providing Access to Healthcare

BP

:   Blood pressure

CDM

:   Chronic Disease Management Program

CVD

:   Cardiovascular disease

DALY

:   Disability adjusted life year

FGD

:   Focus group discussion

HIT

:   Health information technology

ICC

:   Intra-class correlation

LMICs

:   Low- and middle-income countries

MDD

:   Minimum detectable difference

mHealth

:   Mobile technology in health tools

MOH

:   Ministry of health

MTRH

:   Moi Teaching and Referral Hospital

NCD

:   Non-communicable disease

SBP

:   Systolic blood pressure

SD

:   Standard deviation

STRENGTHS

:   Strengthening Referral Networks for Management of Hypertension Across the Health System
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